Magnesium compositions and uses thereof for neurological disorders
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A01N-025/08
A01N-059/06
A61K-033/06
출원번호
US-0402648
(2012-02-22)
등록번호
US-8637061
(2014-01-28)
발명자
/ 주소
Liu, Guosong
Mao, Fei
출원인 / 주소
Magceutics, Inc.
대리인 / 주소
Wilson Sonsini Goodrich & Rosati
인용정보
피인용 횟수 :
6인용 특허 :
16
초록▼
A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of application
A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided.
대표청구항▼
1. A dosage form formulated for oral administration to a subject comprising magnesium threonate, wherein the dosage form comprises at least 10 mg magnesium threonate, and wherein the dosage form is a solid, semi-solid, semi-liquid, or a gel. 2. The dosage form of claim 1, comprising at least 500 mg
1. A dosage form formulated for oral administration to a subject comprising magnesium threonate, wherein the dosage form comprises at least 10 mg magnesium threonate, and wherein the dosage form is a solid, semi-solid, semi-liquid, or a gel. 2. The dosage form of claim 1, comprising at least 500 mg magnesium threonate. 3. The dosage form of claim 1, comprising about 10 mg to about 800 mg magnesium threonate. 4. The dosage form of claim 1, wherein the dosage form comprises about 30 mg to about 1.5 g of elemental magnesium. 5. The dosage form of claim 1, wherein the dosage form comprises about 50 mg to about 800 mg elemental magnesium. 6. The dosage form of claim 1, wherein the dosage form is a solid. 7. The dosage form of claim 1, wherein the dosage form is a gel, semi-liquid or semi-solid. 8. The dosage form of claim 1, comprising elemental magnesium at a concentration of at least about 5 mg/L. 9. The dosage form of claim 1, comprising elemental magnesium at a concentration of from about 5 mg/L to about 12 g/L. 10. The dosage form of claim 1, further comprising a nutritionally active agent. 11. The dosage form of claim 10, wherein the nutritionally active agent is selected from the group consisting of: a calcium-containing material, an herbal, a spice, vitamin A, vitamin D, a vitamin E, a vitamin K, a vitamin B, folic acid, niacin, biotin, a mineral, and mixtures thereof. 12. The dosage form of claim 1 that is a tablet. 13. The dosage form of claim 1 that is a capsule. 14. A method of providing magnesium supplementation to a subject, comprising: orally administering to the subject the dosage form of claim 1. 15. The method of claim 14 wherein the subject suffers from Attention Deficit Hyperactivity Disorder (ADHD), Parkinson's disease (PD), schizophrenia, fatigue, hypertension, or anxiety. 16. The method of claim 14, comprising providing about 1.5 mg/kg of body weight/day to about 18 mg/kg of body weight/day of elemental magnesium. 17. The method of claim 14, wherein the dosage form is administered for at least about 15 days. 18. The method of claim 14, wherein the dosage form is administered for at least about 4 months. 19. The dosage form of claim 1, wherein the dosage form is a dietary supplement.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (16)
William T. Evans ; Dwight L. McKee, Alkali or alkaline earth metal of n-butyric acid for treatment of cognitive and emotional conditions.
George H. Clark ; Mary Ann Clark, Carbonated fortified milk-based beverage and method of making carbonated fortified milk-based beverage for the supplementation of essential nutrients in the human diet.
Yu Kai,CNX ; Wang Zhiwen,CNX ; Kou Fuping,CNX, L-threonate ferrous, as well as pharmaceutical composition and use for improving and treating human anemia thereof.
Skyler Jay S. (Key Biscayne FL) Frost Phillip (Miami Beach FL) Hahn Elliot F. (North Miami Beach FL), Method and composition for treatment of insulin resistance syndromes.
Glick J. Leslie (Potomac MD), Methods for diagnosing, monitoring and controlling the onset and progression of certain dementias and impeding memory lo.
Atalla Rajai H. (Verona WI) Weinstock Ira A. (Madison WI) Hill Craig L. (Atlanta GA) Reiner Richard S. (Madison WI), Oxidation of lignin and polysaccharides mediated by polyoxometalate treatment of wood pulp.
Costa Jonathan L. (Wheaton IL) Diazgranados Jesus A. (Cali COX), Treatment of human diseases involving dysregulation or dysfunction of the nervous system.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.